Advancements in diagnosis and treatment of meningeal carcinomatosis in solid cancer

Jun-Zhao Cui, Jun-Ying He, Qing Li, Xiao-Qing Li, Rui-Ping Gao, Hui Bu, Yue-Li Zou, Xiao-Su Guo, Wei-Xin Han, Ze-Yan Zhao, Yuan-Yuan Li, Ming-Ming Zheng, Ya-Juan Liu, Li-Tian Yan

Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, China.

Correspondence to: Prof. Jun-Ying He, Department of Neurology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang 050000, Hebei, China. E-mail: hjy_zn@126.com

How to cite this article: Cui JZ, He JY, Li Q, Li XQ, Gao RP, Bu H, Zou YL, Guo XS, Han WX, Zhao ZY, Li YY, Zheng MM, Liu YJ, Yan LT. Advancements in diagnosis and treatment of meningeal carcinomatosis in solid cancer. Neuroimmunol Neuroinflammation 2017;4:167-78.

ABSTRACT

Meningeal carcinomatosis (MC) is a disease that malignant tumor cells cultivate in the cerebrospinal fluid or meninges. With the development of therapy methods and new techniques, survival time of patients with tumor is prolonged, and the incidence of MC is increasing. Diagnosis is based on the evaluation of clinical manifestations, cerebrospinal fluid and neuroimaging findings. Furthermore, in recent years, the diagnostic value of the tumor-derived cell-free DNA in the cerebrospinal fluid (CSF) is promising and may improve the diagnostic yield of CSF analysis. Traditional treatments of MC include surgery, radiation therapy, systemic therapy, and intrathecal therapy. Recently, molecular targeted therapy and immunotherapy have received more and more attention. The authors review the epidemiology, pathogenesis, clinical manifestation, diagnosis and treatment of MC in solid cancer, and discuss the diagnosis and treatment options currently available as well as those under investigation.

INTRODUCTION

Meningeal carcinomatosis (MC), also called neoplastic meningitis is a disease in which intracranial primary tumors or extracranial malignant tumors diffuse, disseminate or focally invade into the meninges and spinal subarachnoid.[1-4] In 1870, Swiss pathologist Eberth[5] demonstrated the selective infiltration of carcinoma cells in the leptomeninges in an autopsy case with lung cancer, while pathological anatomy revealed no inflammation in meninges. The term MC was proposed first to describe the clinical condition.
by Siefert in 1902. This disease was uncommon at that time, and usually confirmed by autopsies. In the past few decades, 10-30% of people with solid tumors progress to nervous system metastasis, with 4-15% developing into MC.[6,7] The metastases most frequently come from carcinoma of the breast, lung, gastrointestinal tract, and melanoma. Adenocarcinoma is the most common histologic types.[8] This disorder is easy to be misdiagnosed because of the diverse clinical manifestations and lack of specificity.

This article systematically reviewed the epidemiology, pathogenesis, clinical manifestation, auxiliary examination, diagnosis, treatment and prognostic aspects.

EPIDEMIOLOGY

With the development of imaging technique and therapies, the survival time of patients with MC is prolonged and the incidence of MC is growing. MC can occur secondary to tumors have not been discovered and in antitumor therapy, which was most common in older individuals. About 4-7% of patients with solid tumor suffer meningeal metastasis,[9-11] with lung cancer (9-25%), gastrointestinal tumor (4-14%), breast cancer (2-5%) and malignant melanoma (23%) as the most common causes. MC can be also detected clinically in 5-15% of patients with hematological malignancies (lymphomatosis or lymphomatous) and primary brain tumors (gliomatosis).[12] However, there are still cancers with an unknown primary (1-7%). Above all, MC is a relatively late event in carcinoma process.

PATHOPHYSIOLOGY

In many MC cases, the damages can be seen in autopsies as brain tissue edema, enlarged cerebral gyrus, meningeal congestion, cerebrospinal membrane greyish white in color, ventriculomegaly on sectioning. Microscopically, tumor cells can be seen in the cerebrospinal membrane and subarachnoid space diffusely or focally, while nodules are not obtained in cerebral parenchyma.

Cancer cells may leave the primary tumor to meningeal by following routes: malignant neoplasms cells may shift to subarachnoid space or cerebral ventricles by hematological invasion, with later spread to the cerebrospinal fluid (CSF). Both the perineural or perivascular spaces and cranial or radicular nerve pathway carry tumor cells to dura mater, leptomeninges, or the ependyma, leading to tumor deposits. Neoplastic cells may spread to the meninges directly.

DIAGNOSIS

The diagnosis of MC may be confirmed on the basis of the National Comprehensive Cancer Network guidelines.[13] The guidelines indicated that any one of the criteria listed below are sufficient to diagnose MC; positive CSF cytology; neuroimaging findings consistent with MC, supportive clinical signs and symptoms and a nonspecific but abnormal CSF changes (increased white blood cell count, decreased glucose, and high protein concentration) in patients suffering from tumor. Despite substantial false negative rate, CSF cytology remains the gold diagnostic standard. In addition to the cytological/neuroimaging/clinical diagnosis, other CSF parameters such as β-glucuronidase, creatine-kinase BB isoenzyme (CK-BB), etc. may be regarded as adjuvant diagnosing for MC and are also used to monitor the treatment response. Furthermore, the diagnostic value of the tumor-derived cell-free DNA in the CSF is promising and may improve the diagnostic yield of CSF analysis.

Clinical characteristics

Multiple interrelated events result in clinical symptoms of MC, such as obstruction of CSF reflux leading to hydrocephalus, nutrient metabolism competition between neoplastic cells and normal cells resulting in neurological function deficit, tumors invasion of Vichow Robin Spaces. Most patients with MC first presented with headache, nausea, vomiting, epilepsy, cervical radicular pain, hemiplegia and unconsciousness. In a cohort of 60 patients with breast cancer leptomeningeal metastases, headache was the most common presenting symptoms (55%), followed by various cranial neuropathies and epilepsy (50% and 12%, respectively). Vertigo presented in 12 patients (20%).[14] Classically, MC presents with various clinical signs and symptoms in three domains of neurologic function: the cerebral hemispheres; the cranial nerves; and the spinal cord and associated roots.[15]

Headache, nausea, vomiting are the most frequent manifestations of cerebral hemisphere dysfunction. Other signs include hemiplegia, aphasia, changes in mental status, seizures and cognitive impairments. However, simple focal ischemic cerebral injury and non-communicating hydrocephalus are uncommon. Diplopia, hearing impairment, hemianopsia, and trigeminal sensory loss are common symptoms of cranial nerve involvement with the VI cranial nerve being the most frequently impaired, followed by cranial nerve III and IV. The most frequent spinal
signs and symptoms include lower motor weakness, dermatomal sensory loss, pain in the neck or back and radiculopathy. Nuchal rigidity is less common which present in less than 15% of cases.\[16,17\]

**CSF examination**

**Routine CSF examination**

Intracranial hypertension (\(> 200 \text{ mmH}_2\text{O}\)) is observed in 46% cases with MC. More than 90% of patients with MC have abnormal routine test and biochemistry indicators in CSF with increased leukocytes (\(> 4/\text{mm}^3\)) in 57%, elevated protein (\(> 50 \text{ mg/dL}\)) in 76%, and decreased glucose (\(< 60 \text{ mg/dL}\)) in 54%.\[18\] The nonspecific routine CSF examination should not dissuade consideration of this diagnosis.

**CSF cytology**

Cytological examination of CSF is still the golden criteria. The literatures reported\[19\] that the sensibility of May-Grunwald Giemsa stain method for diagnosing MC was 75-90%, with the specificity 100%. Prior related foreign researchers\[20\] suggest that the positive rate of CSF cytology with the first lumbar puncture is 45%, which increased to 80-90% with a second CSF exam. Little benefit is obtained from a third lumbar puncture. Of the 42 patients with MC accepted into the trial reported by He et al.\[21\] the sensitivity of a first lumbar puncture is 85.7%, while the tumor cells were found in remaining 14.3% of cases from repeat lumbar punctures. There are still some false positive rates of CSF cytology check. Sometimes it is hard to distinguish the normal cells from the lymphoma cells.

Some simple measures can improve the sensitivity for the diagnosis including CSF sample disposal. The CSF specimen should be processed within an hour after collection which will improve the sensitivity of CSF cytology. Large CSF sampling volumes (\(> 10.5 \text{ mL}\)) is also critical to improve the yield of CSF sensitivity.\[22\] May-Grünwald-Giemsa staining is better than Papanicoulo stain for delineation of nuclear morphological characteristics and cytoplasmic limits. Nonetheless, there remains 25-30% of patients with MC diagnosed based on clinical picture, and radiographic findings, and persistently negative CSF cytology.\[14,16\]

**Tumor markers**

The evaluation of serial biochemical markers in the CSF may be of value in the adjunctive diagnosis of MC and assessment in therapeutic efficacy. Some biomarkers may be nonspecific, such as $\beta$-glucuronidase, CK-BB, lactate dehydrogenase, tissue polypeptide antigen, beta2-microglobulin, carcinoembryonic antigen, vascular endothelial growth factor (VEGF), which can be helpful as indirect indices of MC.\[23,24\] Other tumor markers such as carbohydrate antigen 15-3, carbohydrate antigen, carbohydrate antigen 125, carbohydrate antigen, neuron specific enolase, alfa-fetoprotein, CYFRA 21-1, and epidermal growth factor receptor (EGFR) can be relatively specific for MC when increased in CSF compared to serum.\[25-27\] Combined assay of different markers may enhance the sensitivity of MC diagnosis.\[28\] Occasionally, the biomarkers provide diagnostic support for MC in cases suspected as MC with negative CSF cytology.\[28\] However, detection of tumor cells in the CSF by CSF cytology remains the golden criteria for diagnosis of MC.

**Genetic testing**

When tumors diffuse into the central nervous system (CNS), the patients are usually already in an advanced disease stage and is unresponsive to therapy. Mechanisms of cancer dissemination and development within the CNS are unknown due to limited access to tumor tissue. Sasaki et al.\[29\] analyzed the EGFR mutation status of CSF straightly using real-time polymerase chain reaction that was more sensitive than cytology to diagnose MC in seven patients with non-small cell lung carcinoma (NSCLC) harboring an EGFR mutation (sensitivity of 100% vs. 28.6%). A separate study used next-generation sequencing by Pentsova et al.\[30\] to reveal somatic alterations in tumor-derived DNA from CSF in patients with CNS metastases of solid tumors and primary brain tumors. These studies demonstrated that identification of genomic mutations in tumor-derived cell-free DNA from CSF using a sufficiently sensitive platform in patients with CNS involvement. These techniques may be useful in complementing the diagnosis of MC, monitoring response to therapy and identifying resistance mutations. Therefore, in recent years, CSF has attracted the greatest attention and may be considered as a “liquid biopsy” for patients with MC. Currently, the technology of high-throughput sequencing of CSF may recognize cancer-related DNA in cases with known or suspected CNS involvement, which will provide significant aid for the diagnosis and treatment response.

**Neurological imaging**

Computed tomography (CT) is not sensitive in diagnosing MC with an estimated 23-38% of sensitivity of scan reported.\[31,32\] Magnetic resonance imaging (MRI) is considered the standard for the cancer patients with clinical suggestive of MC.\[33\] The sensitivity of MRI in the diagnoses of MC varied from 20% to 91%.\[11,14,34\] Subarachnoid or ventricular enhancing nodules, diffuse or focal leptomeningeal enhancement, ependymal, sulcal, and nerve root enhancement are common MRI findings in MC. Brain parenchymal metastases can be observed in 21-82% of MC.\[34-37\]
Any stimulation of the pia mater, such as subarachnoid blood, infection and cancer can produce enhancement of MRI. Lumbar puncture itself can induce a meningeal reaction resulting in leptomeningeal enhancement, so it would be better to conduct MRI examination prior the procedure.\textsuperscript{[38]} Nevertheless, negative findings cannot be excluded the diagnosis of MC absolutely.

Researches on radionuclide using either \textsuperscript{111}In-diatetraammine penta-acetic acid or \textsuperscript{99}Tc macroaggregated albumin are regarded as effective technique of choice to monitor and evaluate CSF flow dynamics.\textsuperscript{[39,40]} CSF flow blocks have been demonstrated in 30-70% of patients with MC, with blocks usually arises in the skull base, within the spine and over the cerebral convexities.\textsuperscript{[40,41]} Patients with CSF flow obstruction confirmed by radionuclide show shorter survival time when compared with those with normal CSF flow.\textsuperscript{[42,43]} Managements of affected areas radiotherapy to the location of CSF flow obstruction resume flow in 30% of patients with spinal affected and in 50% of patients with intracranial involved.\textsuperscript{[44]}

**TREATMENT**

Treatment of MC focuses on two aspects: therapy toward meningeal involvement and toward the primary cancer. In other words, patients with MC were given meningeal involvement therapy based on the primary cancer. As almost all patients with MC have been in advanced stage at presentation, palliative treatment such as radiotherapy, chemotherapy, biotherapy and molecular targeted therapy, etc. are usually the main treatment for primary tumor. Current treatments for meningeal involvement include surgery, radiation therapy (RT), systemic therapy, and intrathecal therapy, molecular targeted therapy and immunotherapy. Treatment should be targeted at alleviating the neurological symptoms, improving the quality of life and prolonging the survival time for the patients with MC. Therapy toward meningeal involvement mainly from the following aspects introduced.

**Surgery**

The main operative treatment in MC is ventriculo-peritoneal shunting for hydrocephalus due to CSF circulatory disorders and implantation of intraventricular reservoir for administration of cytotoxic chemotherapy drugs. Communicating hydrocephalus often occurs in patients with MC leading to symptoms of intracranial hypertension. Increased intracranial pressure can be relieved by surgery with a ventriculoperitoneal shunt to improve clinical symptoms if hydrocephalus continues. If possible, an on-off valve may be placed to permit the administration of intra-CSF chemotherapy.\textsuperscript{[45,46]} Moreover, lumboperitoneal shunting may also be a therapeutic option in relieving clinical symptoms of intracranial hypertension in MC.\textsuperscript{[47,48]} There are two types of reservoirs that be generally inserted in a region in the right frontal lobe: the Rickham reservoir, which be placed over a burr hole, and the Ommaya reservoir, a domed shape device that could be easily palpated.\textsuperscript{[49]} The objective is to ensure a more uniform distribution of the drug within the subarachnoid space and to improve the curative effect of drug.

**Radiotherapy**

Radiotherapy is an integral part of MC therapy for patients with a syndrome of cauda equina, coexisting parenchymal brain metastases and CSF flow disturbance, which will alleviate symptoms, reduce bulky tumors volume and rectify CSF flow obstructions. Irradiation range of the whole brain irradiation (WBRT) include the cerebral meninges, basis cranii, basilar cistern, and the spinal canal to the plane of cervical vertebrae 1 and 2. WBRT is usually recommended at a dose of 30-36 Gy in fractions of 3 Gy, 40 Gy in 2 Gy fractions administered to patients with favorable prognosis,\textsuperscript{[45]} for cases with a poor prognosis 5 × 4 Gy is an alternative to shortens the course of treatment.\textsuperscript{[50]} It relieved pain and alleviated nervous system symptom but demonstrated no benefit to improve survival.\textsuperscript{[34]} Craniospinal irradiation is rarely administered in MC because of its significant bone marrow toxicity. Focal radiotherapy can be administered safely in patients with bulky disease and obstructive lesions in short periods using a single dose via stereotactic radiosurgery, which is beneficial for patients with obvious syndrome of radicular pain and can result in reduced use of pain medicine.\textsuperscript{[45]} In general, symptoms usually can be controlled after RT.\textsuperscript{[51,52]}

**Chemotherapy**

**Intrathecal therapy**

Intrathecal chemotherapy is generally regarded as a modality to evade the blood-brain barrier (BBB) and blood-CSF barriers in MC. Four chemotherapy agents are received FDA approval for intrathecal injection: methotrexate (MTX), cytosine arabinoside (Ara-C), liposomal Ara-C, and thiotepa, with methotrexate as the broadest used drug in the treatment of MC. As antimetabolites, MTX and Ara-C are the firm rock in medical practice for MC caused by any primary cancer in decades. Liposomal Ara-C has similar curative effect, but its advantage lies in decreased frequency of intrathecal injection.\textsuperscript{[53]} Additionally, trastuzumab and topotecan has recently been used in intrathecal chemotherapy in MC from breast cancer.\textsuperscript{[54-56]} Topotecan, an alkylating agent, showed variable
In addition, IV administration also shows several advantages in pharmacokinetics which can make the physician be more efficient during clinical practice. In addition, IV administration also shows several advantages compared with intralumbar treatment. The process is indolent for the patients and would help physician be more efficient during clinical practice. In addition, IV administration also shows several advantages in pharmacokinetics which can make the drugs distribute uniformly in the entire subarachnoid ventricular spaces. An improved OS was obtained for intraventricular administration compared with intralumbar chemotherapy in one clinical study of breast cancer patients with MC.

Methotrexate. MTX is an anti-folate agent that inhibits dihydrofolate reductase necessary for the synthesis of folic acid required for DNA synthesis and tumor growth. The half-life of MTX is around 4-8 h. MTX is administered on a twice-weekly schedule for treatment induction and followed by weekly administration for consolidation. The following schedules have been recommended. MTX induction: 10-15 mg twice a week for 4 weeks. Consolidation: 10-15 mg once a week for 1 month and then every 2 weeks for 2 months. Maintenance: 10-15 mg every 4-8 weeks.

Cytosine arabinoside. Ara-C, a pyrimidine analogue, inhibits the synthesis of DNA. The half-life of ara-C is approximately 3.4 h in the CSF, which is much longer than in serum because the cytidine deaminase is low in CSF. The traditional ara-C will be completely cleared from the CSF within 1-2 days. Similar to MTX, ara-C should be administered twice a week for treatment induction. Ara-C is relatively ineffective for MC secondary to solid tumors, but is a well established treatment for lymphomatous meningitis. Liposomal ara-C, a depot encapsulated form of ara-C (DepoCyt), provides a therapeutic ara-C concentration in the CSF for as many as 10-12 days with a half-life of 140 h. Intra-CSF administration of the liposomal ara-C may be once every 2 weeks. A randomized trial analyzed the survival rate difference in solid tumor-related MC treated with intra-CSF liposomal ara-C and MTX and there was no marked significant difference between the two groups (median survival 105 vs. 78 days). The improvement in median time to neurologic progression with intra-CSF liposomal ara-C administration improved neurologic progression free survival (PFS) and reduced times of hospitalization for patients. The schedule of intra-CSF administration as follows: liposomal ara-C induction: 50 mg every 2 weeks in weeks 1 and 3. Consolidation: 50 mg every 2 weeks in weeks 5, 7 and 9, followed by an additional dose at week 13. Maintenance: 50 mg every 4 weeks in weeks 17, 21, 25 and 29. Ara-C is initially administered at a dosage of 25-100 mg twice weekly with a 4-week induction, followed by 25-100 mg once weekly for 4 weeks of consolidation and 25-100 mg once a month for subsequent maintenance. If cytarabine is delivered intraventricularly, a dose reduction of 50% should be considered.

Thiotepa. Thiotepa, an alkylating agent, inhibits the cell cycle nonspecifically and available for routine intra-CSF chemotherapy. It shows the shortest half-life of all drugs used for intra-CSF chemotherapy with approximately 20 min and is cleared completely.
in CSF within 4 h.

Intrathecal administration of thiopeta may be used in second-line treatment regimens for breast cancer-related MC patients who show poor response or fail to tolerate intra-CSF MTX. A randomized trial demonstrated that MC patients treated with intra-CSF MTX had significantly longer median survival compared with intra-CSF thiopeta (16 vs. 14 weeks). Thiopeta Induction: 10 mg 2 or 3 times weekly for 4 weeks. Consolidation: 10 mg once weekly for 4 weeks. Maintenance: 10 mg once a month.

Innovative intra-CSF chemotherapy regimens. The growing number of patients with tumor who develop MC boost the investigation of new intra-CSF chemotherapeutic agents such as topotecan, alpha interferon, trastuzumab, rituximab.

(1) Topotecan. Topotecan, a topoisomerase I inhibitor, shows anticancer activity against various solid tumors of adult and childhood. A phase I study has shown a response in 3 out of 13 children received IT topotecan with primary brain tumors-related MC. It is not clear if Topotecan, with good tolerability, produces any added benefit compared to other intra-CSF therapies. Therefore, IVent topotecan combined with other IVent agents may be an option due to its good tolerance profile. The treatment program is as follows. Induction: 0.4 mg twice a week for 6 weeks. Consolidation: 0.4 mg twice a week for 6 additional doses. Maintenance: 0.4 mg twice monthly for 4 months and then monthly thereafter; (2) biological modifiers. Intra-CSF administration of interleukin-2 has been evaluated in cases with MC secondary to melanoma. As previously reported with systemic therapy, some cases showed a long-term clinical response but some side-effects of therapy appeared. In addition, interferon-alpha exhibited a moderate activity in a phase II trial of 22 patients with MC from a wide variety of solid tumor (median period of response: 16 weeks), combined with a transient chemical arachnoiditis and cumulative fatigue in most cases; (3) monoclonal antibodies. In clinical studies, intra-CSF administration of monoclonal antibodies which targets the tumor antigens have been performed in patients with MC from solid tumors including breast cancer, ovarian cancer, melanoma and showed a rare long period of response (7-26 months).

Trastuzumab. Approximately 3-5% of HER 2 positive breast cancer patients develop meningeal metastasis unlike the parenchymal brain metastasis (about 30%). Primary tumor tissues and CSF neoplastic cell share tumor HER 2 status. Trastuzumab CSF/serum ratios vary from 0.0023 mg/dL to 0.02 mg/dL in patients with MC regardless of WBRT, which result in very limited CSF concentration of trastuzumab. The clinical practice of intra-CSF trastuzumab shows clinical and cytological success in patients with MC from HER-2 positive breast cancer. A patient with MC received 67 cycles of weekly 25 mg IT trastuzumab with a long survival time (27 months) after MC diagnosis and dramatic clinical improvement. Moreover, intra-CSF trastuzumab combined with intra-CSF MTX and ara-C has been performed in two patients with MC. The survival time of the two patients was 13.5 months and 6 months respectively with a clinical benefit and without substantial toxicity. Intra-CSF administration of trastuzumab remains experimental and additional experience and data are required before consideration as a standard treatment.

Bevacizumab. Bevacizumab, an angiogenic inhibitor, target the VEGF ligand. Several studies showed higher levels of VEGF in CSF in patients with MC, supporting the hypothesis that angiogenesis promotes MC. The correlation coefficient was negative between VEGF and survival in these patients. Bevacizumab is clinically approved metastatic colorectal cancer and NSCLC. Retrospective study manifested that bevacizumab was found to be safe in CNS metastases without inducing intracranial hemorrhage. The assessment of intra-CSF injection of bevacizumab is ongoing in MC. A pilot study of 15 patients with MC showed that bevacizumab resulted in a dramatically decreased CSF VEGF level and relief of clinical symptoms. Furthermore, a preclinical rabbit model of MC treated with intra-CSF bevacizumab has been evaluated.

Systemic chemotherapy

The advantage of intra-CSF chemotherapy in solid tumors-related MC pales in comparison to hematological malignant tumor because of inborn chemical resistance, limited intra-CSF chemotherapy drugs availability, and the insufficient accessibility of large nodules to intra-CSF chemotherapy. In addition, MC is always accompanied with systemic disease, so it is reasonable to use systemic chemotherapy to simultaneously treat systemic disease and MC. Treatment options of intra-CSF and systemic chemotherapy have been evaluated in solid tumors-related MC. The overall response rate, the long-term survival rate and the median survival of patients with solid tumors-related MC who underwent intra-CSF chemotherapy combined with systemic chemotherapy and radiotherapy did not change despite increased neurotoxicity. Another prospective
study in patients with MC from NSCLC concluded that adding systemic chemotherapy to combined intra-CSF chemotherapy and radiotherapy did not improve the survival time due to insensitivity of the type of cancer.\cite{93} Data from a retrospective study of 135 patients showed that the management of systemic chemotherapy is closely related to a longer survival time, which is a significant positive prognostic factors in patients with MC.\cite{94} However, the choice of the systemic chemotherapy seems to be based not only on the chemical sensitivity of the primary tumor but also on its ability to pass through the blood-brain-barrier and the effective concentrations of drug in the CSF, which can image the chemical characteristics of the systemic agent. Treatment with high-dose intravenous MTX and cytarabine achieved therapeutic CSF levels in patients with hematological malignancy and MC from breast cancer.\cite{22}

Myelosuppression is the dose-limiting factor of these treatment schedules. Moreover, these agents are toxic and limited by their narrow spectrum of activity in most solid tumors.

**Molecular targeted therapy**

Recently, the application of molecular targeted drugs in the clinic have achieved breakthrough results in patients with MC who show mutations in the $EGFR$ gene or rearrangement of the anaplastic lymphoma kinase ($ALK$) gene in lung tumor, amplification of human epidermal growth factor receptor 2 ($HER2$) gene in breast cancer, and positivity of CD20 in B cell lymphoma.

Mutations in the $EGFR$ gene and rearrangement of the $ALK$ gene are the two the most frequently studied types of genetic mutations in NSCLC. Identification of the mutation status of the $EGFR$ gene is crucial because patients harboring $EGFR$ gene mutations are highly sensitive to $EGFR$ tyrosine kinase inhibitor (TKI). $EGFR$ mutations are independent positive prognostic factors in patients with NSCLC-related MC.\cite{95,96} Liao et al.\cite{97} indicated that MC patients receiving $EGFR$ TKI therapy with an $EGFR$ mutation showed longer overall survival compared with those without the mutation (10.9 months vs. 2.3 months, $P < 0.001$). $EGFR$ TKI can pass through the BBB at levels of 1-3%.\cite{98} A study demonstrated that high-dose gefitinib (750 or 1,000 mg daily) improves neurologic symptoms and achieve therapeutic levels in CSF in 57% of NSCLC patients with MC who is sensitive to $EGFR$ TKI.\cite{99} Erlotinib showed higher concentration in CSF (28.7 vs. 3.7 ng/mL, $P = 0.0008$) compared to gefitinib.\cite{99} Moreover, a retrospective study indicated that the cytologic transformation rates in erlotinib treatment group were higher (64.3% vs. 9.1%, $P = 0.012$) than gefitinib treatment group in NSCLC with MC.\cite{100} In addition, afatinib is an FDA-approved second-generation $EGFR$ TKI for NSCLC with $EGFR$ mutations and the effective treatment for CNS metastasis (brain metastasis or MC) in NSCLC who had an inadequate response to erlotinib or gefitinib.\cite{101}

However, there are no reports of the curative effect of afatinib in patients with MC who failed high-dose $EGFR$ TKI. Osimertinib (AZD9291), a third-generation $EGFR$ TKI, showed effectiveness in an in vivo MC model with a first-and second-generation $EGFR$ TKI resistant.\cite{102}

Rearrangement of the $ALK$ gene is observed in around 4-5% of NSCLC patients. Identifying $ALK$ rearrangement is important because patients with rearrangement of the $ALK$ gene can be effectively treated with $ALK$ inhibitors.\cite{103} Crizotinib, a first-generation $ALK$ inhibitor, shows poorly BBB permeability with a CSF-to-plasma ratio of 0.26, so the CNS remains a frequent site of recurrence for $ALK$-positive cases treated with crizotinib.\cite{104,105} Several case reports showed a higher brain-to-plasma ratio of the second-generation $ALK$ inhibitors (ceritinib or alectinib) compared to first-generation $ALK$ inhibitors and better efficacy against MC for $ALK$ positive patients with brain metastases.\cite{106,107} Evidence from studies show that second-generation $ALK$ inhibitors, especially ceritinib, may be treatment choices in MC patients from $ALK$-positive NSCLC.\cite{108}

Amplification of $HER2$ is found in about 15-20% of breast cancer cases.

Trastuzumab is a monoclonal antibody that acts via the $HER2$ receptor and is effective for patients with $HER2$-positive breast cancer.\cite{109} However, the effects have been limited due to BBB permeability in MC. Stemmler et al.\cite{79} found that the ratio of serum trastuzumab to CSF trastuzumab in patients with brain metastases from breast cancer was 420:1 before radiation, 76:1 after radiotherapy, and 49:1 in cases with accompanied MC after radiotherapy. Trastuzumab is a highly effective intrathecal chemotherapy agent that can be used independently, or in combination with other drugs, for the management of MC from $HER2$-positive breast cancer.\cite{106,111,112} Several studies revealed that intrathecal trastuzumab can be used safely and efficiently for $HER2$-positive breast cancer patients with MC with a wide dose range of 4-150 mg.\cite{113} Laptatinib, as a dual TKI of $HER1$ and $HER2$ is effective for $HER2$-positive breast cancer patients who have progressed while on trastuzumab.\cite{114,115} Nevertheless, there has been no reported data on laptatinib for
treatment of MC. Therefore, intrathecal trastuzumab is the only targeted therapy for MC in patients with HER2-positive breast cancer.

Rituximab, an anti-CD20 monoclonal antibody, shows efficacy in patients with diffuse large-B-cell lymphoma, its effects in MC are limited because of its large molecular size leading clinicians to study intrathecal rituximab. A case-series analysis of relapsed CNS lymphoma demonstrated that intraventricular administration of rituximab showed efficacy in six cases. Intraventricular rituximab was administered in dose of 10-40 mg, produced a total elimination rate of malignant cells in CSF for three patients and a disappearance of leptomeningeal lymphoma nodules in one patient. Therefore, these results show the potential of intrathecal rituximab for patients of MC with CD20-positive lymphoma.

Vemurafenib, a BRAF inhibitors, possesses a good perspective in late stage of melanoma patients with BRAF mutation. In a case report, vemurafenib showed clinical and imaging responses and improvement of survival time.

Immunotherapy
CpG-28, a Toll-like receptor 9 (TLR-9) agonist, can boost both the innate and the adaptive immune system through stimulation of TLR-9 and have antineoplastic activity in animal models. In a phase I trial, 29 patients with MC received injection of CpG-28 both subcutaneously and intrathecally, which indicated the tolerance and feasibility of intrathecal injection with CpG-ODN for cases with MC. The median PFS was 7 weeks and OS was 15 weeks. This new immunostimulating agent was also used in patients with recurrent glioblastoma, which showed good security and some cases of mild reactions. Based on the current study results from each phase of clinical trials, immunotherapy has become a new direction of clinical researches on MC.

CONCLUSION
MC is the third most common CNS metastatic complication of systemic cancer with extremely poor prognosis. We summarized the epidemiology, pathophysiology, clinical manifestation, diagnosis and various therapeutic managements for solid tumor-related MC. The symptomatology is characterized by high intracranial pressure (headache, nausea, vomiting, consciousness disorder), cranial nerve involvement and radicular symptoms. The correct diagnosis depends on the contrast-enhanced magnetic resonance imaging of the spine and brain in combination with the cytological CSF analysis. In addition, the technology of high-throughput sequencing of CSF which recognizes cancer-related DNA will provide significant reference for the diagnosis in clinics. Traditional treatments including surgery, RT, systemic chemotherapy and intrathecal chemotherapy, but the prognosis for MC remains very poor with a median survival of < 3 months. Recently, molecular targeting treatment and immunotherapy have been applied to MC and have shown breakthrough results. The prognosis of MC may be affected by several factors such as age, performance status, primary tumor histology. Age of more than 50, low Karnofsky performance status, lung cancer or malignant melanoma as primary tumor may be the negative prognostic factors in cases with MC. Therefore, precise diagnostic techniques remain to be investigated, and novel therapeutic targets need to be found to improve the life quality and prolong the survival time for the patients with MC.

DECLARATIONS
Authors’ contributions
Study concept and design: J.Y. He
Manuscript drafting: J.Z. Cui
Manuscript revising: Q. Li
Data collection: X.Q. Li, R.P. Gao, H. Bu

Financial support and sponsorship
None.

Conflicts of interest
There are no conflicts of interest.

Patient consent
There is no patient data involved.

Ethics approval
Not applicable.

REFERENCES
43. Mason WP, Yeh SD, DeAngelis LM. 111Indium-diethylene triamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of
75. Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon
104. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases (LM) in


